BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jul 04, 2011
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 7/1 cls
Ardea Biosciences Inc. (NASDAQ:RDEA) Stifel, Nicolaus Maged Shenouda New Buy 7% $26.56
Shenouda initiated with a $32 target on the commercial potential of lesinurad (RDEA594) to treat gout. He said the selective inhibitor of solute carrier family 22 organic anion urate transporter member 12 (SLC22A12; URAT1) has blockbuster potential, and estimated global sales could...

Read the full 478 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >